Nephrology · 2015 · 14 citations · 23 references
MedicineCardiologyPharmacotherapyInterventional CardiologyRenal PathophysiologyRenal PharmacotherapyAcute Kidney InjuryChronic Kidney DiseaseDiabetic Kidney DiseaseDiabetic NephropathyRenal DiseaseRenal ImpairmentContrast-induced Kidney InjuryContrast-induced NephropathyCoronary Ct AngiographyCystatin CCystatin C-based AssessmentInvasive Coronary AngiographyRenoprotective TherapiesSerum Creatinine Assessment
AIM: Contrast-induced-nephropathy (CIN) is associated with poor outcomes, thus prevention of CIN may be of clinical value. Erythropoietin (EPO) has been shown to elicit tissue-protective effects in experimental models and in clinical studies of acute kidney injury. We therefore evaluated its effectiveness for prevention of CIN after coronary angiography (CA) ± percutaneous coronary intervention (PCI) in diabetic patients with chronic kidney disease. METHODS: A prospective, randomized, controlled trial was carried out in 138 diabetic patients with eGFR <60 mL/min who underwent non-urgent CA ± PCI. Patients received normal saline and n-acetyl cysteine before CA, with or without 50,000 U of EPO administered 30 min prior to CA. CIN was defined as an increase in serum creatinine of at least 0.5 mg/dL during the first 2 days after exposure to contrast media. Primary outcome was the incidence of CIN. Secondary outcomes were the sensitivity and positive predictive value (PPV) of Cystatin C (CC) and Neutrophil-gelatinase-associated-lipocalin (NGAL) for diagnosis of CIN. RESULTS: The observed incidence of CIN was 8.7%, significantly lower than the expected for such high-risk population. The administration of EPO prior to CA did not reduce the incidence of CIN (9.7% vs. 7.6%, P = 0.65). CC and NGAL demonstrated a low sensitivity (16.6%) and low PPV (6.7 and 33.3%, respectively) for detecting CIN. CONCLUSION: The administration of EPO prior to CA did not reduce the incidence of CIN. Additional prospective research with a larger sample size and in other patient categories is essential to further define the potential protective effect of EPO on prevention of CIN.
23
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Hannelore Ehrenreich, Martin Hasselblatt, Christoph Dembowski et al. · Molecular Medicine · 2002 · 1K citations · Full text
Erythropoietin regulates endothelial progenitor cells
Ferdinand H. Bahlmann, Kirsten de Groot, Jens-Michael Spandau et al. · Blood · 2003 · 500 citations